Company Description
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States.
Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency.
The company’s PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia.
In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera.
Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2007 |
| IPO Date | Jul 24, 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 540 |
| CEO | Brian Goff |
Contact Details
Address: 88 Sidney Street Cambridge, Massachusetts 02139 United States | |
| Phone | 617 649 8600 |
| Website | agios.com |
Stock Details
| Ticker Symbol | AGIO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001439222 |
| CUSIP Number | 00847X104 |
| ISIN Number | US00847X1046 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Brian M. Goff M.B.A. | Chief Executive Officer and Director |
| Cecilia Jones | Chief Financial Officer |
| James William Burns | Chief Legal Officer |
| Dr. Krishnan Viswanadhan M.B.A., Pharm.D. | Chief Corporate Development and Strategy Officer |
| Dr. Sarah Gheuens M.D., Ph.D. | Chief Medical Officer and Head of Research and Development |
| Dr. Lewis clayton Cantley Ph.D. | Co-Founder |
| Dr. Tak Wah Mak D.Sc., FRSC, Ph.D. | Co-Founder |
| Dr. Craig B. Thompson M.D. | Co-Founder |
| Dr. Shin-San Su Ph.D. | Co-Founder |
| T. J. Washburn | Vice President, Controller and Principal Accounting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 29, 2026 | SCHEDULE 13G | Filing |
| Apr 29, 2026 | 10-Q | Quarterly Report |
| Apr 29, 2026 | 8-K | Current Report |
| Apr 24, 2026 | ARS | Filing |
| Apr 24, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 24, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 2, 2026 | 144 | Filing |
| Apr 2, 2026 | 144 | Filing |
| Apr 2, 2026 | 144 | Filing |
| Apr 2, 2026 | 144 | Filing |